Literature DB >> 26398477

Twin-Arginine Translocation Peptide Conjugated Epirubicin-Loaded Nanoparticles for Enhanced Tumor Penetrating and Targeting.

Luzhong Zhang1, Fan Liu2, Guicai Li3, Youlang Zhou4, Yumin Yang5.   

Abstract

One major obstacle in the application of drug delivery systems for cancer chemotherapy is their poor penetration in tumor tissues. Conjugating active ligand moieties to the surface of nanoparticles may be a promising approach for enhancing the tumor accumulation and penetration of nanoparticles. Herein, the cell-penetrating peptide twin-arginine translocation (Tat)-conjugated epirubicin-loaded poly(lactic-glycolic acid) nanoparticles were prepared to achieve deep tumor penetration. The morphology and size of nanoparticles were characterized by scanning electron microscopy and dynamic light scattering, and the biological behaviors of nanoparticles were evaluated. It is demonstrated that Tat-conjugated nanoparticles have a significant improvement in antitumor activity and biodistribution compared with nonconjugated nanoparticles. Importantly, Tat conjugated on the surface of nanoparticles could facilitate the encapsulated drug penetration into deeper tumor tissue. Additionally, Tat-conjugated nanoparticles have good biocompatibility, as demonstrated by hemolytic tests, in vitro cytotoxicity, and histology study. These results suggested that the Tat-conjugated nanoparticles, as a powerful delivery system for chemotherapeutic drug, would have a promising application in human cancer therapy.
© 2015 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  Tat peptide; conjugaton; controlled release; drug delivery; epirubicin; nanoparticle; poly(lactic/glycolic) acid; tumor penetration

Mesh:

Substances:

Year:  2015        PMID: 26398477     DOI: 10.1002/jps.24649

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

Review 1.  PVAT: an important guardian of the cardiovascular system.

Authors:  Xiuying Liang; Yan Qi; Fan Dai; Jingya Gu; Wenjuan Yao
Journal:  Histol Histopathol       Date:  2020-02-21       Impact factor: 2.303

Review 2.  Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine.

Authors:  Mauro Sousa de Almeida; Eva Susnik; Barbara Drasler; Patricia Taladriz-Blanco; Alke Petri-Fink; Barbara Rothen-Rutishauser
Journal:  Chem Soc Rev       Date:  2021-03-05       Impact factor: 54.564

3.  Internal cross-linked polymeric nanoparticles with dual sensitivity for combination therapy of muscle-invasive bladder cancer.

Authors:  Guanchen Zhu; Kaikai Wang; Haixiang Qin; Xiaozhi Zhao; Wei Chen; Linfeng Xu; Wenmin Cao; Hongqian Guo
Journal:  J Nanobiotechnology       Date:  2020-09-04       Impact factor: 10.435

Review 4.  Combination of Cell-Penetrating Peptides with Nanoparticles for Therapeutic Application: A Review.

Authors:  Sara Silva; António J Almeida; Nuno Vale
Journal:  Biomolecules       Date:  2019-01-10

5.  Meta-Analysis of Nanoparticle Delivery to Tumors Using a Physiologically Based Pharmacokinetic Modeling and Simulation Approach.

Authors:  Yi-Hsien Cheng; Chunla He; Jim E Riviere; Nancy A Monteiro-Riviere; Zhoumeng Lin
Journal:  ACS Nano       Date:  2020-03-04       Impact factor: 15.881

6.  Influence of bound dodecanoic acid on the reconstitution of albumin nanoparticles from a lyophilized state.

Authors:  Christian C E Luebbert; Rola Mansa; Raisa Rahman; Zygmunt J Jakubek; Grant E Frahm; Shan Zou; Michael J W Johnston
Journal:  Sci Rep       Date:  2021-02-26       Impact factor: 4.996

7.  Mannose-decorated ginsenoside Rb1 albumin nanoparticles for targeted anti-inflammatory therapy.

Authors:  Zhihui Fu; Xiaohui Wang; Xuan Lu; Ying Yang; Lingling Zhao; Lin Zhou; Kaikai Wang; Hanlin Fu
Journal:  Front Bioeng Biotechnol       Date:  2022-08-15

8.  Doxorubicin-loaded redox-responsive micelles based on dextran and indomethacin for resistant breast cancer.

Authors:  Yunfang Zhou; Shuanghu Wang; Xuhua Ying; Yifan Wang; Peiwu Geng; Aiping Deng; Zhihong Yu
Journal:  Int J Nanomedicine       Date:  2017-08-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.